A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exatecan (Primary)
- Indications Rhabdomyosarcoma
- Focus Therapeutic Use
- 15 May 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2005 New trial record.